Blood disorders
Multiple myeloma
多发性骨髓瘤Myeloma
A cancer of mature plasma cells that make a single abnormal antibody. Typical features are bone damage, bone pain and fractures, often with anaemia, high blood calcium and kidney problems.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 178
- cities
- 58
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 22% of the world's English-language research papers on multiple myeloma, 2021–2025 (14% in 2016–2020), and 12% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
178 hospitals in 58 cities
Order: papers led on multiple myeloma, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 3 papers or 1 trial on multiple myeloma, or was a site in 3 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens multiple myeloma in that city. 48 more cities are in the menu below.
- 59 papers ledNo open trial led
- 55 papers led
- 52 papers ledNo open trial led
- 47 papers led
- 37 papers led
- 30 papers led
- 27 papers led
- 27 papers led
- 27 papers led
- 26 papers led
- 24 papers led
- 24 papers led
- 23 papers led
- 22 papers ledNo open trial led
- 19 papers led
- 19 papers ledNo open trial led
- 19 papers led
- 18 papers ledNo open trial led
- 18 papers ledNo open trial led
- 17 papers led
- 17 papers ledNo open trial led
- 17 papers led
- 17 papers ledNo open trial led
- 16 papers led
- 16 papers ledNo open trial led
- 15 papers led
- 15 papers ledNo open trial led
- 14 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers led
- 11 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers led
- 10 papers ledNo open trial led
- 9 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 7 papers led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 1 paper ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 57
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 80 papers led4 hospitals
- 66 papers led6 hospitals
- 66 papers led5 hospitals
- 63 papers led4 hospitals
- 53 papers led6 hospitals
- 50 papers led4 hospitals
- 50 papers led3 hospitals
- 50 papers led6 hospitals
- 49 papers led6 hospitals
- 46 papers led3 hospitals
- 41 papers led3 hospitals
- 39 papers led6 hospitals
- 39 papers led4 hospitals
- 38 papers led5 hospitals
- 37 papers led6 hospitals
- 30 papers led2 hospitals
- 28 papers led6 hospitals
- 28 papers led5 hospitals
- 28 papers led4 hospitals
- 25 papers led4 hospitals
- 24 papers led6 hospitals
- 21 papers led2 hospitals
- 20 papers led5 hospitals
- 17 papers led5 hospitals
- 17 papers led3 hospitals
- 16 papers led2 hospitals
- 16 papers led1 hospital
- 16 papers led5 hospitals
- 15 papers led6 hospitals
- 12 papers led2 hospitals
- 12 papers led5 hospitals
- 12 papers led5 hospitals
- 12 papers led1 hospital
- 12 papers led2 hospitals
- 11 papers led1 hospital
- 10 papers led3 hospitals
- 10 papers led3 hospitals
- 10 papers led5 hospitals
- 10 papers led1 hospital
- 8 papers led1 hospital
- 7 papers led3 hospitals
- 6 papers led2 hospitals
- 5 papers led1 hospital
- 5 papers led1 hospital
- 5 papers led1 hospital
- 5 papers led4 hospitals
- 5 papers led3 hospitals
- 5 papers led2 hospitals
- 4 papers led1 hospital
- 4 papers led1 hospital
- 3 papers led2 hospitals
- 3 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 1 paper led1 hospital
- 1 paper led1 hospital
open trials on multiple myeloma in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 118 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingA Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT07255898
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-02
- Registry
- NCT07258511
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an
- RecruitingIASO206 in Patients With Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2026-01
- Registry
- NCT07322159
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- Phase
- Phase 1
- Started
- 2026-02
- Registry
- NCT07409246
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Tianjin
- RecruitingMRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07409454
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
- Phase
- Early phase 1
- Started
- 2026-03
- Registry
- NCT07429721
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-03
- Registry
- NCT07452198
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingTo Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Registry
- NCT07454187
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Suzhou, Xi'an, Zhengzhou
- RecruitingA Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07477587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Phase I Study of SHR-3836 in Patients With Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-06
- Registry
- NCT07490613
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou
- RecruitingA Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2026-04
- Registry
- NCT07493135
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPredicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study
- Phase
- Not given
- Started
- 2026-01
- Registry
- NCT07514052
Age 18 years to Not stated (registered criteria)
Led by Shanxi Bethune HospitalTaiyuan
- RecruitingA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07518186
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an
- RecruitingAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07523555
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingStudy to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT07529782
Age Not stated to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Suzhou, Tianjin
- RecruitingCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07555938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingA Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07579234
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingCM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07585760
Age 18 years to 80 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingSafety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
- Phase
- Phase 1
- Started
- 2026-09
- Registry
- NCT07620275
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General Hospital; 2 listed hospitals as study sitesBeijing, Tianjin
- RecruitingA Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07623798
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07638683
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Clinical Study of SHR-5421 in Patients With Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07652281
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingCM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07652905
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingGPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
- Phase
- Phase 1
- Started
- 2026-06
- Registry
- NCT07660939
Age 18 years to 80 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingIsatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07663253
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou
- RecruitingA Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Registry
- NCT07760454
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Suzhou
- RecruitingCD38 Targeted -PET/ CT for Multiple Myeloma
- Phase
- N/A
- Started
- 2026-07
- Registry
- NCT07782944
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Guilin Medical UniversityGuilin
- RecruitingPhase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
- Phase
- Phase 1
- Started
- 2026-09
- Registry
- NCT07914556
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingMobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT06514508
Age 18 years to 78 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2025-04
- Registry
- NCT06717113
Age 18 years to 80 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingA Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT06730256
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingSafety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-01
- Registry
- NCT06758713
Age 18 years to 75 years (registered criteria)
Led by Third Affiliated Hospital of Southern Medical UniversityGuangzhou
- RecruitingA Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2025-01
- Registry
- NCT06791681
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingBCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06793449
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingAponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT06793475
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingKPD Consolidation After ASCT in NDMM Patients
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Registry
- NCT06879379
Age 18 years to Not stated (registered criteria)
Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing, Shanghai
- RecruitingBCMA CAR-T for Dynamic High-risk Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06880393
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingGR1803 Injection in Patients With RRMM
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06952075
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingIntravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT06961669
Age 3 years to Not stated (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingA Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
- Phase
- Early phase 1
- Started
- 2025-05
- Registry
- NCT06976437
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Jiangsu UniversityChangzhou
- RecruitingA Study of CT0596 in Plasma Cell Leukemia
- Phase
- Early phase 1
- Started
- 2025-06
- Registry
- NCT06988059
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Registry
- NCT06988488
Age 18 years to Not stated (registered criteria)
Led by Shanghai Fourth People's HospitalShanghai
- RecruitingDual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT07003555
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingDual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT07003568
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingPhase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07018050
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingSafety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
- Phase
- Early phase 1
- Started
- 2025-06
- Registry
- NCT07085559
Age 19 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingLCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- N/A
- Started
- 2025-09
- Registry
- NCT07100067
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan
- RecruitingAn Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
- Phase
- Early phase 1
- Started
- 2025-09
- Registry
- NCT07101705
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07106671
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07106684
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07106710
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingMRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07106736
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingAutologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT07109323
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingClinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT07169500
Age 18 years to 50 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- Phase
- Phase 1
- Started
- 2025-12
- Registry
- NCT07179679
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an
- RecruitingUniversal CAR-T Cell Therapy for MM
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT07248176
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalShanghai
- RecruitingCAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2025-03
- Registry
- NCT07249073
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07294625
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 4 listed hospitals as study sitesNanjing, Shanghai, Xi'an, Xuzhou, Zhengzhou
- RecruitingReal-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT07296627
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07297329
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingRandomised Controlled Trial of Artificial Intelligence-assisted Health Education
- Phase
- N/A
- Started
- 2025-06
- Registry
- NCT07305337
Age 18 years to 90 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- RecruitingA Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07312188
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Recruiting68Ga-BCMA PET/CT in Multiple Myeloma
- Phase
- Phase 2/Phase 3
- Started
- 2025-12
- Registry
- NCT07319897
Age 18 years to 80 years (registered criteria)
Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing, Changchun, Shijiazhuang
- RecruitingNovel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- N/A
- Started
- 2025-11
- Registry
- NCT07359014
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingClinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2025-10
- Registry
- NCT07369895
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingPrevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
- Phase
- Phase 3
- Started
- 2025-10
- Registry
- NCT07413809
Age 18 years to 65 years (registered criteria)
Led by Affiliated People's Hospital of Ningbo UniversityNingbo
- RecruitingStudy of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07489534
Age 14 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingEpunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07497165
Age 18 years to 75 years (registered criteria)
Led by Shanxi Bethune HospitalTaiyuan
- RecruitingIL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07509086
Age 18 years to 80 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingSafety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07652138
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingLow-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07763054
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Central South UniversityHaikou
- RecruitingA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06083207
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou
- RecruitingThe Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT06228794
Age 18 years to 80 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
- Phase
- Phase 1/Phase 2
- Started
- 2024-02
- Registry
- NCT06232096
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingUTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- N/A
- Started
- 2024-04
- Registry
- NCT06279026
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou
- RecruitingStudy of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-05
- Registry
- NCT06375044
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou
- RecruitingPET Imaging Study of 68Ga-NB381 in Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2024-04
- Registry
- NCT06385652
Age 18 years to 90 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingStudy of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2024-06
- Registry
- NCT06407947
Age 18 years to Not stated (registered criteria)
Led by Changzheng HospitalShanghai
- RecruitingTreatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
- Phase
- Phase 4
- Started
- 2024-06
- Registry
- NCT06409702
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingA Clinical Study of SHR-9539 in Patients With Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-08
- Registry
- NCT06484777
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingPurinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Registry
- NCT06484829
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingA Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06497738
Age 65 years to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 2 listed hospitals as study sitesChangzhou, Nanjing, Nantong
- RecruitingA Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06508983
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingComparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
- Phase
- Phase 3
- Started
- 2024-08
- Registry
- NCT06520176
Age 18 years to 75 years (registered criteria)
Led by Affiliated People's Hospital of Ningbo University; 6 listed hospitals as study sitesHangzhou, Ningbo, Taizhou, Wenzhou
- RecruitingIntestinal Flora and Immunity in Monoclonal Gammopathy Patients
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06539832
Age 45 years to Not stated (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingA Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-06
- Registry
- NCT06574568
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou
- RecruitingChimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT06581640
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingA Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
- Phase
- Phase 1
- Started
- 2024-10
- Registry
- NCT06644118
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingConversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06682156
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingCharacteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06690593
Age 45 years to Not stated (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingRisk Stratification and MRD-driven Maintenance for MM After ASCT
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06697483
Age 18 years to Not stated (registered criteria)
Led by Peking University People's Hospital; 2 listed hospitals as study sitesBeijing, Harbin
- RecruitingA Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06700395
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Shanghai
- Recruitinga Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
- Phase
- Early phase 1
- Started
- 2024-12
- Registry
- NCT06718270
Age 18 years to Not stated (registered criteria)
Led by Changzheng HospitalShanghai
- RecruitingBCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06745687
Age 18 years to 78 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingThe Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Registry
- NCT06911710
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingA Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2024-09
- Registry
- NCT06999031
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Nanchang UniversityNanchang
- RecruitingLong-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT07028970
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Tianjin, Wuhan, Zhengzhou
- RecruitingAspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
- Phase
- Phase 4
- Started
- 2024-02
- Registry
- NCT07907211
Age 18 years to 70 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingSafety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Registry
- NCT05565807
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou
- RecruitingScreening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
- Phase
- Not given
- Started
- 2023-01
- Registry
- NCT05686447
Age not stated (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingA Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- Phase
- Phase 1
- Started
- 2023-03
- Registry
- NCT05759793
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingThe China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
- Phase
- Not given
- Started
- 2023-07
- Registry
- NCT05965115
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingHelical Tomotherapy in Multiple Myeloma
- Phase
- N/A
- Started
- 2023-06
- Registry
- NCT05970198
Age 18 years to 75 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- RecruitingA Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
- Phase
- Phase 2
- Started
- 2023-08
- Registry
- NCT05979363
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingCardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
- Phase
- Not given
- Started
- 2023-11
- Registry
- NCT06039735
Age 18 years to 70 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingTo Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
- Phase
- Early phase 1
- Started
- 2023-07
- Registry
- NCT06045091
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2023-10
- Registry
- NCT06049290
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingElranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- Phase
- Phase 4
- Started
- 2023-10
- Registry
- NCT06057402
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan
- RecruitingStudy to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- Phase
- Phase 2
- Started
- 2023-10
- Registry
- NCT06140966
Age 18 years to 70 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingDVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT06158269
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingAll-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
- Phase
- Phase 2
- Started
- 2023-11
- Registry
- NCT06158412
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingOriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
- Phase
- Phase 1/Phase 2
- Started
- 2023-10
- Registry
- NCT06182696
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Nanjing, Shanghai, Wuhan
- RecruitingSafety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
- Phase
- Phase 1/Phase 2
- Started
- 2023-12
- Registry
- NCT06196255
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou
- RecruitingMitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2023-11
- Registry
- NCT06246162
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Nantong UniversityNantong
- RecruitingDara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
- Phase
- Not given
- Started
- 2023-06
- Registry
- NCT06252792
Age 18 years to Not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingPrimary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
- Phase
- Not given
- Started
- 2023-12
- Registry
- NCT06463717
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingLongitudinal Data Registry of Plasma Cell Dyscrasia
- Phase
- Not given
- Started
- 2023-03
- Registry
- NCT06760052
Age 19 years to 99 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
- Phase
- N/A
- Started
- 2023-12
- Registry
- NCT06783816
Age not stated (registered criteria)
Led by Shanxi Bethune HospitalTaiyuan
- RecruitingHigh-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
- Phase
- Not given
- Started
- 2023-09
- Registry
- NCT07205523
Age not stated (registered criteria)
Led by Affiliated Hospital of Qinghai UniversityXining
- RecruitingAPRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2022-05
- Registry
- NCT04657861
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Phase
- Phase 4
- Started
- 2022-03
- Registry
- NCT05201781
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
- RecruitingA Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- Phase
- Phase 1
- Started
- 2022-03
- Registry
- NCT05219721
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingPhase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Phase
- Phase 3
- Started
- 2022-09
- Registry
- NCT05243797
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou
- RecruitingMecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- Phase
- Phase 2
- Started
- 2022-04
- Registry
- NCT05294055
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou
- RecruitingA Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2022-08
- Registry
- NCT05299424
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2022-11
- Registry
- NCT05521802
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2022-10
- Registry
- NCT05552222
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingHuman BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
- Phase
- Phase 2
- Started
- 2022-07
- Registry
- NCT05594797
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Wenzhou
- RecruitingThe Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
- Phase
- N/A
- Started
- 2022-09
- Registry
- NCT05618041
Age 14 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTaiyuan
- RecruitingA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05623020
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
- Phase
- Phase 1/Phase 2
- Started
- 2022-07
- Registry
- NCT05632380
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingIxazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
- Phase
- Phase 4
- Started
- 2022-07
- Registry
- NCT05722405
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Started
- 2021-02
- Registry
- NCT04634552
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Suzhou, Tianjin, Xi'an
- RecruitingCD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
- Phase
- Early phase 1
- Started
- 2021-11
- Registry
- NCT04662294
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Registry
- NCT04973605
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Phase
- Phase 3
- Started
- 2021-10
- Registry
- NCT05020236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
- Phase
- Not given
- Started
- 2021-07
- Registry
- NCT05283993
Age not stated (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingIndividualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
- Phase
- Not given
- Started
- 2021-09
- Registry
- NCT06099912
Age 65 years to Not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingValue of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
- Phase
- Early phase 1
- Started
- 2020-08
- Registry
- NCT04504526
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- RecruitingNational Longitudinal Cohort of Hematological Diseases
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT04645199
Age not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingComparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
- Phase
- Phase 1/Phase 2
- Started
- 2019-07
- Registry
- NCT04025450
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingBCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
- Phase
- Phase 1
- Started
- 2019-07
- Registry
- NCT04162353
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingStudy of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2016-09
- Registry
- NCT03196414
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingStudy of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Started
- 2027-12
- Registry
- NCT07695740
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingIsa-VRD in TIE HRMM
- Phase
- Phase 4
- Started
- 2026-01
- Registry
- NCT07334535
Age 18 years to 80 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingApplication Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
- Phase
- N/A
- Started
- 2026-02
- Registry
- NCT07353554
Age 18 years to 85 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingA Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- Phase
- N/A
- Started
- 2026-02
- Registry
- NCT07376720
Age 18 years to 78 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingA Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
- Phase
- Early phase 1
- Started
- 2026-01
- Registry
- NCT07399444
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesNanchang, Tianjin, Wuhan, Xuzhou, Zhengzhou
- Not yet recruitingA Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
- Phase
- Early phase 1
- Started
- 2026-04
- Registry
- NCT07539233
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingClinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07569757
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou
- Not yet recruitingSafety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2026-07
- Registry
- NCT07628595
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingSonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
- Phase
- Phase 1/Phase 2
- Started
- 2026-08
- Registry
- NCT07687004
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingA Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
- Phase
- Phase 4
- Started
- 2026-07
- Registry
- NCT07709884
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingA Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07726160
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingA Open-Label Phase in Participants With Multiple Myeloma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07764861
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingHP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07811986
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingCM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07830485
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingQLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- Phase
- Phase 2
- Started
- 2026-12
- Registry
- NCT07903636
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingStudy of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-12
- Registry
- NCT07910903
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingAspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
- Phase
- Phase 3
- Started
- 2025-09
- Registry
- NCT06580223
Age 18 years to 90 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingA Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Registry
- NCT06799676
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesWuhan, Zhengzhou
- Not yet recruitingA Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2025-04
- Registry
- NCT06895512
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingComparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06963866
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou
- Not yet recruitingPhase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
- Phase
- N/A
- Started
- 2025-07
- Registry
- NCT07034755
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou
- Not yet recruitingRisk-adapted Therapeutic Strategy in +1q NDMM
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07045168
Age not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- Not yet recruitingA Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Registry
- NCT07090954
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Xi'an
- Not yet recruitingRN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07113496
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingRN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07114432
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingStudy of CM336 in Relapsed or Refractory Multiple Myeloma Patients
- Phase
- Phase 3
- Started
- 2025-09
- Registry
- NCT07181239
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
- Phase
- Not given
- Started
- 2025-12
- Registry
- NCT07320326
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingTo Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2024-03
- Registry
- NCT06298266
Age 18 years to 75 years (registered criteria)
Led by Guangdong Second Provincial General HospitalGuangzhou
- Not yet recruitingA Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06369935
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingLCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- N/A
- Started
- 2024-07
- Registry
- NCT06472479
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 2 listed hospitals as study sitesHefei, Nanjing, Zhengzhou
- Not yet recruitingA Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-08
- Registry
- NCT06500507
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingAllogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06594211
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingA Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
- Phase
- Phase 1
- Started
- 2022-04
- Registry
- NCT05181501
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangzhou, Hefei, Nanjing
- Not yet recruitingA Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2021-01
- Registry
- NCT04670055
Age 30 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingA Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy
- Phase
- Early phase 1
- Started
- 2020-12
- Registry
- NCT04541368
Age 30 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Enrolling by invitationLong-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
- Phase
- Not given
- Started
- 2026-11
- Registry
- NCT07833046
Age not stated (registered criteria)
Led by Renji HospitalShanghai
- Enrolling by invitationAI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities
- Phase
- Not given
- Started
- 2018-08
- Registry
- NCT07410403
Age not stated (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- Enrolling by invitationAutologous Stem Cell Transplantation for Patients With AL Amyloidosis
- Phase
- Not given
- Started
- 2010-07
- Registry
- NCT04210791
Age 18 years to 75 years (registered criteria)
Led by Jinling HospitalNanjing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Additional research sources
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
National guideline (China)
No national diagnosis and treatment guideline for this disease was found on the National Health Commission website (searched 10 November 2026).
Where these numbers come from
Papers
1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.